Myriad Genetics: Empowering Precision Medicine for Prostate Cancer With Comprehensive Genomic Testing Solutions
Myriad Genetics, committed to advancing healthcare innovation, celebrates the recent updates to the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guidelines. These updates underscore the indispensable role of Myriad’s diverse portfolio in supporting patients throughout their prostate cancer journey.
"Myriad’s portfolio uniquely supports a patient’s entire prostate cancer journey, distinguishing us in the field of oncology," stated Dr. George Daneker, President and Chief Clinical Officer, Oncology at Myriad Genetics. "
From initial diagnosis through treatment and ongoing management, our goal is to deliver unparalleled accuracy and clarity at every stage of the disease. The updated NCCN guidelines further validate the significance of our comprehensive solutions, including diagnostic testing, multigene germline testing, and tumor molecular profiling.
Furthermore, Myriad provides customizable workflow solutions and access to genetic experts to guide clinicians in providing the most informed and personalized care for their patients."
Myriad’s full suite of urologic oncology diagnostics are uniquely aligned with these guideline updates, offering integrated genetic and tumor genomic insights.
These insights identify individuals at risk for previous, provide vital insights into tumor biology.
A Closer Look at NCCN Guidelines and Myriad’s Role:
The latest Prostate Cancer Guidelines highlight the importance of genomic testing across multiple stages of prostate cancer, further validating Myriad’s leading products.
- Multigene Germline Testing:
The NCCN recommends multigene germline testing for men with metastatic, regional (node-positive), very-high-risk localized, or high-risk localized prostate cancer, regardless of family history.
Myriad’s MyRisk® Hereditary Cancer Test is highlighted embedded here. Click here Test evaluates 48 genes associated with hereditary cancer risk, empowering clinicians to make guided treatment decisions and identify potential risks for family members.
- Comprehensive Management Emphasized:
These
guidelines highlight the necessity for comprehensive management of prostate cancer, incorporating vital
genetic insights.
The Prolaris® Prostate Cancer Test, developed by Myriad, is noteworthy here.Prolaris quantifies prostate cancer aggressiveness and helps personalize treatment pathways,
including when to pursue or forgo treatment, and Myriad continues to driving personalized medicine forward.
Specifically, Prolaris remains the only biomarker test quantifying the absolute benefit
of adding androgen deprivation therapy (ADT) to radiation therapy (RT), ensuring
optimal patient outcomes.
Tailored Treatment Decisions:
Myriad’s MRS reads here. The OO県の test offers multigene tumor profiling, includiag Ind here, for advanced prostate cancer, and
Tumor biomarker assessment of
